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Aging is associated with an increased incidence of cancer. One contributing factor
could be modulation of immune cells responsible for anti-tumor responses, such as
dendritic cells (DCs) and T cells. These immunological changes may also impact the
efficacy of cancer immunotherapies in the elderly. The effects of healthy aging on DCs
and T cells, and their impact on anti-mesothelioma immune responses, had not been
reported. This study examined DCs and T cells in young (2–5 months; equivalent to
16–26 human years) and elderly (20–24 months; equivalent to 60–70 human years)
healthy and mesothelioma-bearing C57BL/6J mice. During healthy aging, elderly lymph
nodes adopted a regulatory profile, characterized by: (i) increased plasmacytoid DCs, (ii)
increased expression of the adenosine-producing enzyme CD73 on CD11c+ cells, and
(iii) increased expression of multiple regulatory markers (including CD73, the adenosine
A2B receptor, CTLA-4, PD-1, ICOS, LAG-3, and IL-10) on CD8+ and CD4+ T cells,
compared to lymph nodes from young mice. Although mesotheliomas grew faster in
elderly mice, the increased regulatory status observed in healthy elderly lymph node
DCs and T cells was not further exacerbated. However, elderly tumor-bearing mice
demonstrated reduced MHC-I, MHC-II and CD80 on CD11c+ cells, and decreased
IFN-γ by CD8+ and CD4+ T cells within tumors, compared to young counterparts,
implying loss of function. An agonist CD40 antibody based immunotherapy was less
efficient at promoting tumor regression in elderly mice, which may be due to: (i) failure
of elderly CD8+ T cells to up-regulate perforin, and (ii) increased expression of multiple
regulatory markers on CD11c+ cells and T cells in elderly tumor-draining lymph nodes
(including CD73, PD-1, ICOS, LAG-3, and TGF-β). Our findings suggest that checkpoint
blockade may improve responses to immunotherapy in elderly hosts with mesothelioma,
and warrants further investigation.
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INTRODUCTION
There is an increased incidence of cancer with aging, and
one contributing factor could be age-induced modulation of
immune cells that mediate anti-tumor immune responses, such
as dendritic cells (DCs) and T cells. DCs are antigen-presenting
cells that play an important role in initiating anti-tumor immune
responses, on account of their ability to activate tumor-specific
CD8+ cytotoxic T cells, which can directly kill tumor cells
and mediate tumor regression (1–5). There is some evidence
that aging influences DC anti-tumor function, with DCs from
elderly mice shown to have a reduced ability to stimulate tumor-
specific cytotoxic CD8+ T cells in vivo (6, 7). Furthermore,
administration of DC vaccines to elderly tumor-bearing mice
leads to generation of weak cytotoxic T cell activity, and does
not slow tumor growth, resulting in a shorter survival time
(8, 9). Age-related defects in murine T cell anti-tumor function
have also been reported, these include; reduced numbers of
tumor-antigen-specific T cells, decreased proliferative capacity,
impaired cytotoxic activity, and reduced production of effector
cytokines, such as interferon (IFN)-γ and IL-2, in elderly
tumor-bearing mice (10–18). However, the effects of healthy
aging on DCs and T cells, and the potential impact on
generation of anti-tumor immune responses in mesothelioma, an
asbestos-induced cancer which occurs predominantly in elderly
populations aged 60 years and above (19, 20), have not yet been
reported.
Furthermore, age-related changes in DCs and T cells may
impact on the efficacy of cancer immunotherapies in the elderly.
The few studies performed to-date that have considered aging
indicate that cancer immunotherapies are less effective in elderly
hosts (6, 8, 9, 11, 21–25). Little is known about the effects
of aging on responses to immunotherapy in mesothelioma.
Our previous studies, using young mice (1.5–2 months of age,
equivalent to 16–26 human years), have shown that intra-
tumoral administration of IL-2 in combination with agonist
anti-CD40 antibody (IL-2/CD40) induces permanent regression
of large AE17 mesothelioma tumors mediated by CD8+ T
cells, neutrophils (26), B cells (27) and pro-inflammatory M1
macrophages (28). Cured mice remained tumor-free for the
remainder of their natural lives and were protected from tumor
re-challenge by CD8+ and CD4+ T cells and natural killer cells
(29, 30). Studies from our laboratory have also shown that elderly
macrophages activated with in vitro IL-2 and agonist anti-CD40
antibody restore the capacity of elderly CD8+ T cells to produce
IFN-γ and perforin (31, 32). Here, we extend these studies to
investigate the influence of aging on DC and T cell function
during treatment with IL-2/CD40 in vivo.
The aim of this study was to examine the influence of
aging on DC and T cell function in healthy mice vs. mice
with mesothelioma, and to examine responses to IL-2/CD40
immunotherapy in elderly and young mesothelioma-bearing
mice. We compared DCs and T cells from young (2–5 months;
equivalent to 16–26 human years) (33) and elderly C57BL/6J
mice (20–24 months; equivalent to 60–70 human years) (33, 34)
in: (i) lymph nodes of healthy mice, and (ii) tumor-draining
lymph nodes and tumors of mesothelioma-bearing mice, with
and without IL-2/CD40 immunotherapy. We examined the
effects of aging on DC and T cell subset proportions, as well as
expression of activation/effector and regulatory markers.
MATERIALS AND METHODS
Mice
This project was approved by the Curtin University Animal
Ethics Committee (approval number AEC-2012-21), and all
experiments were performed according to the Australian Code
of Practice for the care and use of animals for scientific purposes.
Young (2–5 months; equivalent to 16–26 human years) (33)
and elderly (20–24 months; equivalent to 60–70 human years)
(33, 34) female C57BL/6J mice were obtained from the Animal
Resources Center (Western Australia, Australia) and maintained
under specific pathogen-free conditions in the Curtin University
animal facility. For studies involving healthy mice, any mice that
had a palpable mass, enlarged lymph nodes, enlarged spleen,
or enlarged liver were excluded to ensure that only healthy,
non-tumor-bearing mice were examined.
Murine Mesothelioma Cell Line Culture
AE17 is a murine mesothelioma cell line derived from the
peritoneal cavity of C57BL/6J mice injected with asbestos fibers,
as previously described (35). AE17sOVA was developed by
transfecting the AE17 parental cell line with cDNA coding for
secretory ovalbumin (OVA), hence ovalbumin, which contains
the SIINFEKL peptide, functions as a marker tumor antigen,
as previously described (35). AE17 cells were cultured in
complete medium, consisting of RPMI 1640 media (Invitrogen,
California, USA), supplemented with 10% fetal calf serum
(FCS; ThermoScientific, Victoria, Australia), 100 units/ml of
penicillin and 100µg/ml streptomycin (Penicillin-Streptomycin;
Life Technologies, Victoria, Australia) and 2mM L-glutamax
(Life Technologies). AE17sOVA cells were maintained in
complete medium supplemented with 400 µg/L of the neomycin
analog G418 (Geneticin; Life Technologies, Grand Island, USA).
All cells were cultured at 37◦C in a 5% CO2 atmosphere.
Murine Tumor Growth and Treatment With
IL-2/CD40 Immunotherapy
For tumor inoculation, mice were injected subcutaneously in
the right flank with 5 x 105 AE17 or AE17sOVA tumor cells
per mouse, in 100 µl of PBS. Tumor growth was monitored
and tumor size was measured daily using microcallipers. The
maximum tumor size allowed was 140 mm2 in accordance
with ethics approval from the Curtin University Animal Ethics
Committee.
For immunotherapy, AE17 or AE17sOVA tumor-bearing
mice were treated intra-tumorally once every 2-3 days with PBS
diluent (100 µl/dose) or interleukin-2 (IL-2, 20 µg/dose; Cetus
Corporation, California, USA) and agonist anti-CD40 antibody
(FGK45, 40 µg/dose; Absolutions, Western Australia, Australia)
as previously described (26), for 5 doses in total.
Processing and Staining Murine Tissues
for Flow Cytometric Analysis
Mice were euthanized using methoxyflurane (Medical
Developments International, Victoria, Australia). Spleens and
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lymph nodes were collected from healthy (non-tumor-bearing)
mice, and tumors and tumor-draining lymph nodes were
collected from AE17 tumor-bearing mice for flow cytometric
analysis. For samples that required intracellular cytokine
staining, murine tissues were collected into FACS buffer [1 ×
PBS/1% newborn calf serum (NCS)/1% bovine serum albumin
(BSA)] + 2.5µg/ml brefeldin A (Sigma), and incubated for 4 h
prior to staining. Lymph nodes and tumors were disaggregated
into single-cell suspensions by gentle dispersion between two
frosted glass slides.
Single-cell suspensions of murine lymph nodes and tumors
were stained with fluorescently-labeled antibodies to identify DC
subsets (CD11c, CD11b, CD8, CD4, B220, and GR-1; Table 1),
T cell subsets (CD3, CD8, CD4, CD25, and FoxP3; Table 1),
and activation (MHC-I, MHC-II, CD40, CD80, CD86, IFN-γ,
IL-12, TNF-α, and/or perforin; Table 1) and regulatory markers
(CD39, CD73, A2AR, A2BR, PD-L1, GAL-9, IL-10, TGF-β
latency-associated peptide, ICOS, LAG-3, CTLA-4, and/or PD-1;
Table 1).
Samples were incubated with surface primary antibodies
(diluted in FACS buffer + 2.5µg/ml brefeldin A) for 30min at
4◦C in the dark, and washed twice in FACS buffer + 2.5µg/ml
brefeldin A by centrifuging at 1,200 rpm for 2min. Samples
stained with purified A2BR antibody or biotinylated primary
antibodies (B220, CD11c, CD39, and PD-1) were incubated
with goat anti-rabbit IgG-AF488 (Invitrogen) or streptavidin-
V500 (BD), respectively (diluted in FACS buffer + 2.5µg/ml
brefeldin A), for 30min at 4◦C in the dark. Samples were washed
twice in FACS buffer + 2.5µg/ml brefeldin A, followed by two
PBS washes, then stained with Zombie green or Zombie NIR
viability dyes (both from Biolegend) for 15min at 4◦C in the
dark, washed twice in FACS buffer, then twice in PBS. Cells
were fixed in 1% paraformaldehyde (Sigma) diluted in PBS by
incubating for 20min at 4◦C in the dark, washed twice with
FACS buffer, and permeabilised with FACS buffer+ 0.1% saponin
(Sigma) for 15min at 4◦C in the dark. For samples requiring
FoxP3 staining, cells were fixed using FoxP3 Fix/Perm buffer
(Biolegend), permeabilised using FoxP3 Perm buffer (Biolegend),
then stained with FoxP3 antibody (1 µl/well) for 30min at 4◦C
in the dark, washed twice in FACS buffer + 0.1% saponin, then
stained with other intracellular antibodies. Cells were stained
with intracellular primary antibodies (diluted in FACS buffer
+ 0.1% saponin) for 30min at 4◦C in the dark, then washed
twice in FACS buffer. Samples stained with TGF-β-biotin were
incubated with streptavidin-V500 (diluted in FACS buffer+ 0.1%
saponin) for 30min at 4◦C in the dark, followed by two washes
using FACS buffer, and resuspended in 200 µl of FACS buffer per
well. Samples were stored at 4◦C in the dark (up to a maximum
of 1 week) before analysis on a FACSCanto II using FACSDiva
software (BD) or FlowJo software (TreeStar, USA).
In vivo cytotoxic T lymphocyte (CTL) Assay
for Analysis of CTL Function
The cytotoxic activity of tumor-specific CD8+ T cells was
assessed via an in vivo CTL assay, as previously described (27).
Briefly, target cells for this assay were derived from spleen
TABLE 1 | Anti-mouse antibodies used in this study.
Antigen Conjugate Clone Supplier
SURFACE ANTIGENS/MARKERS
Adenosine A2B receptor Purified Polyclonal Alomone Labs
B220 (CD45R) Biotin RA3-6B2 Biolegend
CD3e APC-eFluor780 17A2 eBioscience
CD3e PE 145-2C11 BD
CD4 APC-Cy7 GK1.5 Biolegend
CD4 PerCP-Cy5.5 RM4-5 BD
CD8α AF405 5H10 Invitrogen
CD8α AF647 5H10 Invitrogen
CD8α FITC 53-6.7 Biolegend
CD8α PerCP-Cy5.5 53-6.7 BD
CD11b PE-Cy7 M1/70 BD
CD11c APC HL3 BD
CD11c APC N418 Invitrogen
CD11c Biotin N418 Biolegend
CD11c FITC HL3 BD
CD25 PE-Cy7 PC61 Biolegend
CD39 Biotin 5F2 Biolegend
CD40 PE 3/23 BD
CD73 PE TY/11.8 Biolegend
CD73 PerCP-Cy5.5 TY/11.8 Biolegend
CD80 BV421 16-10A1 BD
CD86 FITC GL1 Biolegend
GR-1 (Ly6C/Ly6G) PE RB6-8C5 BD
ICOS (CD278) Pacific Blue C398.4A Biolegend
LAG-3 (CD223) PerCP-Cy5.5 C9B7W Biolegend
MHC-I (H-2Kb) PerCP-Cy5.5 AF6-88.5 Biolegend
MHC-II (I-A/I-E) APC-Cy7 M5/114.15.2 Biolegend
PD-1 (CD279) Biotin RMP1-30 Biolegend
PD-L1 (CD274) PE-Cy7 10F.9G2 Biolegend
INTRACELLULAR ANTIGENS/MARKERS
Adenosine A2A receptor PerCP-Cy5.5 7F6-G5-A2 Santa Cruz
CTLA-4 (CD152) BV421 UC10-4B9 Biolegend
FoxP3 AF647 150D Biolegend
Galectin-9 PerCP-Cy5.5 RG9-35 Biolegend
IFN-γ PE-Cy7 XMG1.2 Biolegend
IL-10 BV421 JES5-16E3 Biolegend
IL-12 (p40/p70) PE C15.6 BD
Perforin APC eBio0MAK-D eBioscience
TGF-β1 latency-associated
peptide
Biotin TW7-16B4 Biolegend
TNF-α AF647 MP6-XT22 Biolegend
and lymph node cells from healthy young C57BL/6J mice.
Spleen and lymph node cell suspensions were RBC-lysed, washed
and divided into two populations. One population was pulsed
with 10−6 M SIINFEKL peptide for 90min at 37◦C, washed
with PBS, and labeled with a high concentration (5µm) of
carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes,
Oregon, USA). Control target cells (i.e., not pulsed with peptide)
were labeled with a low concentration of CFSE (0.5µm). 107
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cells from each population were pooled in 200 µl PBS and
intravenously injected into each recipient AE17sOVA-bearing
young or elderly mouse. Tumor-draining lymph nodes and
tumors were collected from young and elderly recipient mice
24 h after target cell injection, and the number of cells in each
target cell population in each tissue measured by flow cytometry.
The ratio between the percentages of unpulsed vs. SIINFEKL-
pulsed cells (CFSElo/CFSEhigh) was calculated to obtain a
numerical value of cytotoxicity. To normalize data, allowing
inter-experimental comparisons, ratios between the percentages
of peptide-pulsed cells in control (tumor-free mice and tumor-
bearing PBS-treated mice) vs. age-matched tumor-bearing mice
were calculated.
Data Analysis
Statistical differences between young and elderly populations
were calculated using a Mann-Whitney U-test, using GraphPad
PRISM v7 (GraphPad Software Inc, USA). P < 0.05 were
considered statistically significant.
RESULTS
AE17 Mesothelioma Tumors Grow Faster in
Elderly Mice
We first investigated whether aging influenced AE17
mesothelioma tumor growth in young (2–5 months) vs.
elderly (20–24 months) C57BL/6J mice, and found that tumors
grew faster in elderly mice (Figure 1A) (36). One possibility to
account for faster tumor growth is that aging programs a more
suppressive immune environment that is reflected by DCs and T
cells.
Cross-Presenting DCs Decrease and pDCs
Increase in Elderly Tumor-Bearing Lymph
Nodes
To determine if aging reprograms suppressive DCs, we compared
overall CD11c+ cells (as these antigen presenting cells represent
DCs) and well-described DC subsets in lymph nodes (LNs) and
tumor-draining LNs (TDLNs) from young to elderly healthy
and AE17 mesothelioma-bearing mice using flow cytometry
(Supplementary Figures S1A–S1F).
Neither age nor the presence of a tumor
significantly affected TDLN/LN CD11c+ cell proportions
(Supplementary Figure S1G). However, examination of DC
subsets showed that mesothelioma significantly decreased cross
presenting CD8α+CD11b− cDC (Figure 1B) and T helper 2
(Th2) cell-activating CD11b+CD8α−CD4− cDC proportions
(Figure 1B) in TDLNs compared to LNs from age-matched
healthy mice. In contrast, pDC proportions already increased in
healthy elderly LNs were further elevated in the presence of a
tumor (Figure 1B). No age-related or tumor-induced changes
were observed in CD11b+CD8α−CD4+ cDC proportions
(Figure 1B). These data imply increased suppression due to
loss of cross-presenting DCs alongside increased pDCs that are
suppressive in cancer (37).
Regulatory CD73+CD11c+ DCs Increase in
Elderly Healthy and Tumor-Bearing Lymph
Nodes
To investigate whether antigen-presenting cell function is altered
with aging and mesothelioma, markers of antigen presentation
(MHC-I and II), activation (CD40, CD80, CD86, intracellular
IFN-γ, tumor necrosis factor (TNF)-α and IL-12) and regulation
(CD39, CD73, A2A receptor (A2AR), A2B receptor (A2BR),
programmed cell death ligand-1 (PD-L1), galectin-9 (GAL-9),
intracellular IL-10, and transforming growth factor (TGF)-β
latency-associated peptide) were compared on CD11c+ cells
from young and elderly mice using flow cytometry.
Healthy elderly LNs contained elevated proportions of MHC-
I+CD11c+ cells and CD11c+ cells co-expressing the suppressive
adenosine-producing enzyme CD73, compared to their younger
counterparts (Figures 1C,D) that remained unchanged in the
presence of a tumor in TDLNs (Figures 1C,D). However,
mesothelioma induced age-related differences in TDLNs,
including elevated proportions of IL-12+ and IFN-γ+ CD11c+
cells in elderly TDLNs (Supplementary Figure S1H); this is
despite the observation that, regardless of age, mesothelioma
reduced IL-12+, IFN-γ+, and TNF-α+ CD11c+ cell proportions
in young and elderly TDLNs, compared to age-matched
healthy LNs (Supplementary Figure S1H). These data imply
overall loss of pro-inflammatory function with progressing
mesothelioma. In contrast, mesothelioma increased MHC-II+
and CD80+CD11c+ cells in TDLNs, relative to age-matched
healthy LNs (Supplementary Figure S2A). Expression of
CD80 can be a dual-edged sword as it can ligate CD28 on T
cells leading to T cell activation, or it can ligate cytotoxic T
lymphocyte antigen-4 (CTLA-4) leading to T cell tolerance.
Mesothelioma increased PD-L1 expression on young CD11c+
cells to the same levels as seen in healthy and tumor-bearing
elderly DCs (Supplementary Figure S2B). No other age- or
tumor-induced changes were seen on LN/TDLN CD11c+ cells
(Supplementary Figures S2A–C).
Elderly T cells Increase Expression of
Suppressive CD73, A2BR, CTLA-4, PD-1,
ICOS, LAG-3, and IL-10
As a key function of DCs is activation or tolerization of
T cell responses, we examined the effects of aging and
mesothelioma on T cells in LNs/TDLNs from young and
elderly mice (Supplementary Figures S3A–E). CD4+ T
cell, CD8+ T cell and regulatory T cell (Treg) proportions
reduced in elderly healthy LNs and TDLNs, compared to
young LNs/TDLNs (Supplementary Figure S3F). Tumors
reduced TDLN CD4+ T cell proportions in both age groups
(Supplementary Figure S3F), compared to healthy LNs, yet
did not affect TDLN CD8+ T cell and Treg proportions
(Supplementary Figure S3F).
To investigate function, T cells were stained for markers
of activation (CD25, intracellular IFN-γ and perforin),
and regulation (CTLA-4, programmed cell death protein-1
(PD-1), inducible T cell co-stimulator (ICOS), lymphocyte
activation gene-3 (LAG-3), CD39, CD73, A2AR, A2BR, and
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FIGURE 1 | AE17 mesothelioma tumors grow faster in elderly mice. Young (n = 13) and elderly (n = 15) mice were inoculated subcutaneously with 5 × 105 AE17
tumor cells per mouse, and tumor size (mm2 ) measured daily (A); data shown as mean ± SEM. At end point, TDLNs from the same tumor-bearing mice and LNs from
age-matched healthy mice (n = 32 young and 35 elderly mice) were analyzed for DC subsets (B), MHC-I+ CD11c+ cells (C) and CD73+ CD11c+ cells (D) using flow
cytometry. Data are shown for individual mice as well as mean ± SEM. Mouse numbers for B-D differed on account of varying cell numbers available for analysis and
ranged from n = 11–13 young and n = 12–15 elderly tumor-bearing mice, n = 10–32 young and n = 11–35 elderly healthy mice, *p < 0.05, **p < 0.005,
***p < 0.0005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii) tumor-bearing mice to age-matched healthy mice.
intracellular IL-10 and TGF-β latency-associated peptide) and
analyzed via flow cytometry. Elderly healthy LN and TDLN
CD8+ and CD4+ T cells significantly increased expression
of several regulatory markers, including CD39, CD73, A2BR,
CTLA-4, PD-1, ICOS, LAG-3, IL-10, and TGF-β, compared
to their younger counterparts (Figures 2A,B, 3A,B). Note
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FIGURE 2 | Increased regulatory markers on elderly LN/TDLN CD4+ T cells. Percentages of CD4+ T cells positive for regulatory markers were measured in TDLNs
from the same mice shown in Figures 1A–D young and elderly tumor-bearing mice, and LNs from age-matched healthy young and elderly mice (A,B), via flow
cytometry. Data are shown for individual mice as well as as mean ± SEM, n = 6–11 young and n = 7–12 elderly tumor-bearing mice, n = 6–17 young and n = 6–17
elderly healthy mice, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii) tumor-bearing mice to age-matched healthy
mice.
that the presence of a tumor did not alter healthy age-related
increases in regulatory markers on elderly LN/TDLN T cells
(Figures 2A,B, 3A,B). This suggests that the aging environment
induces LN T cells with suppressive, rather than effector,
function.
The data above and summarized in Table 2 shows that LNs
adopt a regulatory profile with healthy aging, characterized
by increased: (i) pDCs, (ii) CD73 on CD11c+ DCs, and (iii)
multiple regulatory markers on T cells. Furthermore, although
pro-inflammatory CD11b+CD8α−CD4− cDCs and IFN-γ+
and IL-12+ CD11c+ DC proportions were elevated in elderly
TDLNs, suggesting increased T cell-activating potential, this
is undermined by concomitant maintenance of age-related
increases in suppressive DCs and T cells.
The Elderly Tumor Microenvironment
Reduces MHC-I/II and CD80 on DCs and
IFN-γ in T Cells.
We next investigated the tumor microenvironment and found
that elderly tumors contained significantly lower levels of
Th1-activating CD11b+CD8α−CD4+ cDCs compared to young
tumors (Figure 4A). No age-related differences were seen in
the other DC subsets (Supplementary Figure S4A). Elderly
tumor-associated CD11c+ cells significantly reduced MHC-II
and CD80 (Figure 4B), with a trend for reduced MHC-I (p
= 0.08; Figure 4B) relative to their younger counterparts. In
contrast, TNF-α+CD11c+ cells increased in elderly, compared
to young, tumors (Supplementary Figure S4B). Examination
of regulatory markers showed that IL-10+CD11c+ cells
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FIGURE 3 | Increased regulatory markers on elderly LN/TDLN CD8+ T cells. Percentages of CD8+ T cells positive for regulatory markers were measured in TDLNs
from young and elderly tumor-bearing mice, and LNs from age-matched healthy young and elderly mice, as per Figures 1, 2 (A, B), via flow cytometry. Data are
shown for individual mice as well as mean ± SEM, n = 11 young and n = 12 elderly tumor-bearing mice, n = 8 young and n = 9 elderly healthy mice, *p < 0.05,
**p < 0.005, ***p < 0.0005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii) tumor-bearing mice to age-matched healthy mice.
increased (Supplementary Figure S4C), whilst CD39+, PD-
L1+, and TGF-β+ CD11c+ cells decreased in elderly tumors
(Supplementary Figure S4C). These data suggest that aging
induces deficits in elderly tumor-infiltrating CD11c+ cells
leading to reduced antigen-presenting capacity and increased
IL-10-mediated suppression.
An investigation of tumor-infiltrating T cells showed
that CD4+ T cells and Tregs were significantly decreased
in elderly mice (Supplementary Figure S5A), whilst CD8+
T cells were similar with age (Supplementary Figure S5A).
Reduced IFN-γ was seen in CD8+ (Figures 4C,D) and CD4+
T cells (Figure 4C) in elderly tumors compared to young
tumors implying reduced anti-tumor effector T cell activity
with age. Examination of regulatory markers showed increased
CD73+CD8+ T cells (Figure 4D), yet reduced TGF-β+CD8+
T cells (Supplementary Figure S5B), ICOS+CD4+ T cells
(Supplementary Figure S5C) and TGF-β+CD4+ T cells
(Supplementary Figure S5C) in elderly, compared to young
tumors (data also summarized in Table 2), implying different
regulatory age-related mechanisms.
IL-2/Agonist Anti-CD40 Immunotherapy Is
Less Effective in Elderly Mice
Our previous studies demonstrated that IL-2/CD40
immunotherapy induces complete and permanent tumor
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TABLE 2 | Changes to regulatory molecules on LN CD4+ (A) and LN CD8+ (B) T cells with age and IL-2/CD40.
(A) LN CD4+
Y healthy CD4+ E healthy CD4+ Ytumor CD4+ E tumor CD4+ Y IL-2/CD40CD4+ E IL-2/CD40CD8+
CD39 6.5 9.2 3.9 11.5 7.0 15
CD73 32.7 54.7 36.9 52.9 36.1 43.7
A2BR 12.4 24.7 11.0 24.9 16.2 26.1
CTLA-4 13.0 23.3 12.0 31.4 33.2 50.7
PD-1 1.6 5.8 0.6 2.3 2.3 3.3
ICOS 4.1 20.3 6.6 21.5 21.8 48.1
LAG-3 0.4 3.1 0.5 2.3 1.9 3.9
IL-10 1.4 8.6 0.2 1.9 0.5 1.2
TGFP 82.6 88 89.9 94.4 58.5 86.8
(B) LN CD8+
Y healthy CD8+ E healthy CD8+ Y tumor CD8+ E tumor CD8+ Y IL-2/CD40 CD8+ E IL-2/CD40 CD8+
CD39 7.50 10.7 5.4 19.1 10.1 20.5
CD73 63.6 77.1 67.3 75.2 57.4 46.15
CTLA-4 10.1 11.9 8.09 22.5 23.3 34
PD-1 0.1 1.1 0.17 0.9 1.3 7.1
ICOS 1.2 4.9 3.08 7.7 15.31 30.9
LAG-3 1.3 4.1 2.48 4.7 6.3 12.8
TGFP 79.7 88.02 89.02 97.6 60.7 91.1
The means of percentages of LN CD4+ and CD8+ T cells positive for each marker from young (Y) and elderly (E) mice, that are; healthy, tumor-bearing, or tumor-bearing and treated
with IL-2/CD40. The highest percentages relative to each treatment group are highlighted by the darker shade, with a lighter shade showing the second highest levels. T cells from
elderly tumor-bearing mice treated with IL-2/CD40 expressed higher levels of most regulatory markers.
regression in young mice (26, 29, 30). Herein, we investigated
the efficacy of IL-2/CD40 treatment in elderly tumor-bearing
mice. Young and elderly AE17 mesothelioma-bearing C57BL/6J
mice were treated with IL-2/CD40, using previously described
doses (26). A complete schedule of IL-2/CD40 (i.e., 5 doses) was
less effective in elderly mice (45% tumor regression; Figure 5A),
compared to young mice (100% tumor regression; Figure 5A)
(36). Tumors and TDLNs were sampled after mice received one-
third of the treatment schedule (i.e., two doses of IL-2/CD40;
Figure 5A), to enable identification of tumors responding to
treatment and still have enough tumor sample to collect for
analysis, as young mice given the full regimen demonstrate
complete resolution of tumors which therefore cannot be
sampled (26, 29, 30). After two doses, IL-2/CD40 slowed tumor
growth rates in both age groups, although the effects in terms
of tumor size (Figure 5B) and weights (Figure 5C) were more
pronounced in young mice, relative to PBS diluent controls.
IL-2/CD40 Reduces Potential Licensing of
Tumor-Specific T cells by Increasing CD73
and TGF-β and Reducing CD40 on Elderly
but not Young TDLN DCs
Examination of DCs in IL-2/CD40-treated mice showed
that regardless of age CD11b+CD8α−CD4+ cDCs and
CD11b+CD8α−CD4− cDCs (Supplementary Figure S6A)
increased relative to controls, suggesting increased capacity to
stimulate Th1 and Th2 responses. No significant changes were
seen in the other DC subsets (Supplementary Figure S6A).
In both age groups, IL-2/CD40 exerted positive and
negative effects on activation/maturation markers on TDLN
CD11c+ cells: i.e., increased CD80 (Figure 6A) and CD86
(Supplementary Figure S6B), yet reduced IFN-γ, TNF-α and IL-
12 (Supplementary Figure S6B), relative to age-matched PBS
controls. As a result of these changes, elderly IL-2/CD40-treated
mice expressed lower levels of CD80 on CD11c+ cells compared
to their younger counterparts (Figure 6A), whilst CD86, IFN-γ,
TNF-α, and IL-12 expression levels were similar for the two age
groups (Supplementary Figure S6B). Importantly, IL-2/CD40
reduced expression of a number of regulatory markers on young
and elderly TDLN CD11c+ cells including: CD73 (Figure 6A),
TGF-β (Figure 6A), CD39 (Supplementary Figure S6C) and
IL-10 (Supplementary Figure S6C), relative to age-matched
untreated tumor-bearing mice. Nonetheless, CD73 (Figure 6A)
and TGF-β (Figure 6A) remained higher on elderly CD11c+ cells
in IL-2/CD40-treated mice. This suggests that whilst IL-2/CD40
reduces tumor-induced suppressive TDLN CD11c+ cells, it does
not overcome the age-related increase in suppressive CD11c+
cells, which may be a contributing factor to the reduced efficacy
of IL-2/CD40 in elderly mice.
Some age-specific effects were also seen. Young, but
not elderly, IL-2/CD40-treated mice down-regulated MHC-
I (Figure 6B) and MHC-II (Figure 6B) on DCs, relative to
age-matched PBS controls resulting in an increased age-
related differential (Figure 6B). In contrast, CD40 on TDLN
CD11c+ cells reduced (Figure 6B) in elderly, compared to
young, IL-2/CD40-treated mice. Taken together, whilst CD11c+
cells from elderly IL-2/CD40-treated mice have increased
capacity to present antigens to T cells, their ability to license
tumor-specific T cells appears compromised, relative to young
counterparts.
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FIGURE 4 | Reduced CD11b+CD8α−CD4+ cDCs, MHC-I/II, and CD80 on CD11c+ cells, and IFN-γ on T cells in elderly tumors. Young and elderly tumors as per
Figures 1, 2 were analyzed using flow cytometry for percentages of CD11b+CD8α−CD4+ cDCs (A), percentages of CD11c+ cells positive for MHC-I/II and CD80
(B), IFN-γ expression (shown as geometric mean fluorescence intensity; MFI) on CD8+ and CD4+ T cells (C), and percentages of CD8+ T cells positive for IFN-γ and
CD73 (D). Data are shown for individual mice as well as mean ± SEM, n = 11 young and n = 12 elderly tumor-bearing mice, *p < 0.05, **p < 0.005 comparing
young to elderly mice.
IL-2/CD40 Further Exacerbates the
Regulatory Status of Elderly TDLN T Cells
The effects of IL-2/CD40 on CD8+ and CD4+ T cells
and Tregs in TDLNs and tumors were also examined.
IL-2/CD40 reduced TDLN CD4+ T cell proportions
in young and elderly mice, relative to age-matched PBS
controls (Supplementary Figure S7A). Unexpectedly, young
IL-2/CD40-treated mice showed a reduction in TDLN
CD8+ T cell proportions relative to their PBS controls
(Supplementary Figure S7A).
IL-2/CD40 exerted positive and negative effects on regulatory
marker expression on TDLN CD8+ T cells in both age groups,
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FIGURE 5 | IL-2/CD40 is less efficient at inducing tumor regression in elderly mice. Young (n = 24) and elderly (n = 27) mice were inoculated subcutaneously with 5 ×
105 AE17 cells, and tumors left to develop before treatment with intra-tumoral IL-2 (20 µg/dose) and agonist anti-CD40 antibody, 40 µg/dose; n = 10 young and 11
elderly mice or PBS diluent (n = 14 young and 16 elderly mice; 100 µl/dose) for 5 doses, each 2–3 days apart. The shaded bar in (A) represents treatment duration.
Tumor size (in mm2 ) was measured to determine tumor growth rates and response to IL-2/CD40 (A); data shown as mean ± SEM. In a second experiment TDLNs
and tumors were collected for analysis 2–3 days after the second dose, indicated by the black arrow in (A), and tumor sizes (B) and tumor weights (C) in n = 10
young and 11 elderly mice given IL-2/CD40 and n = 14 young and 16 elderly mice given PBS measured; data are shown for individual mice as well as mean ± SEM,
mouse numbers for C differed on account of varying cell numbers available for analysis and ranged from n = 10–13 young and n = 8–16 elderly PBS control mice,
**p < 0.005, ***p < 0.0005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii) IL-2/CD40-treated mice to age-matched PBS control mice.
including increased PD-1, ICOS, and LAG-3 (Figure 7A),
compared to age-matched PBS controls. Nonetheless, age-
related differences in PD-1, ICOS, and LAG-3 were maintained,
whereby elderly CD8+ T cells had higher expression (Figure 7A).
In contrast, IL-2/CD40 induced reduced CD73 and TGF-β
expression on CD8+ T cells (Figure 7B) in young and elderly
TDLNs, relative to age-matched PBS controls. However, IL-
2/CD40-treated young mice demonstrated a striking reduction
in TGF-β, meaning elderly mice still expressed significantly
higher TGF-β (Figure 7B). Overall, elderly TDLN CD8+ T
cells maintain increased suppressive function with IL-2/CD40
treatment.
Interestingly, IL-2/CD40 exerted age-specific effects on TDLN
CD8+ T cell perforin expression, with young mice up-regulating
perforin expression (Figure 7B), resulting in higher expression
compared to elderly IL-2/CD40-treated mice (Figure 7B). This
suggests that in addition to their increased regulatory status,
elderly TDLN CD8+ T cells have reduced cytotoxic effector
activity due to a failure to up-regulate perforin in response to
IL-2/CD40.
IL-2/CD40 also exerted common effects on several regulatory
markers on TDLN CD4+ T cells from both age groups
including increased CTLA-4 and ICOS and decreased
TGF-β expression (Figure 8A), compared to age-matched
PBS controls. Despite these changes, expression of CTLA-
4, ICOS, and TGF-β remained higher on elderly TDLN
CD4+ T cells compared to young IL-2/CD40-treated mice
(Figure 8A).
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FIGURE 6 | IL-2/CD40 increases MHC-I/II, CD80, CD73, and TGF-β on TDLN CD11c+ cells. After two doses of IL-2/CD40 or PBS diluent, percentages of CD11c+
cells positive for CD80, CD73, and TGF-β (A) and MHC-I, MHC-II,. and CD40 (B) were measured in TDLNs from the young and elderly tumor-bearing mice described
in Figures 5B,C using flow cytometry. Data are shown as mean ± SEM, n = 7 young and n = 7 elderly IL-2/CD40-treated mice, n = 11 young and n = 12 elderly
PBS control mice, *p < 0.05, **p < 0.005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii) IL-2/CD40-treated mice to age-matched PBS control mice.
Age-specific effects of IL-2/CD40 on TDLN CD4+ T cells
were also seen. Elderly, but not young, IL-2/CD40-treated mice
reduced CD4+ T cells expressing CD73 (Figure 8B) relative to
controls. CD4+ T cells from young, but not elderly, IL-2/CD40-
treated mice up-regulated CD39, LAG-3, and PD-1 (Figure 8B),
compared to their PBS controls however, this did not alter
the age differentials seen in CD39 and LAG-3 in untreated
mice, with expression of these markers remaining higher on
elderly CD4+ T cells (Figure 8B); data summarized in Tables 2.
Taken together, elderly TDLN CD4+ T cells also demonstrate an
enhanced regulatory status during IL-2/CD40 treatment, which
may contribute to the reduced efficacy of IL-2/CD40 in elderly
mice.
IL-2/CD40 Increases Suppressive TGF-β
and A2BR and Reduces CD40 on DCs in
Elderly Tumors
IL-2/CD40 mostly did not alter young or elderly tumor-
associated DC subset proportions, relative to untreated mice,
with the exception of a small, but significant, increase
in cross-presenting CD8α+CD11b− cDCs in elderly tumors
(Supplementary Figure S7B). The only common effect of
IL-2/CD40 on tumor-associated CD11c+ cells seen in both age
groups was up-regulation of IFN-γ (Figure 9A).
IL-2/CD40 induced several age-specific changes on tumor-
associated CD11c+ cells including increased TGF-β on
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FIGURE 7 | IL-2/CD40 increases PD-1, ICOS, LAG-3, CD73, and TGF-β on TDLN CD8+ T cells. After two doses of IL-2/CD40 or PBS diluent, percentages of CD8+
T cells positive for PD-1, ICOS, and LAG-3 (A) and CD73, TGF-β and perforin (B) were measured in TDLNs from the young and elderly tumor-bearing mice described
in Figures 5B and C using flow cytometry. Data are shown as mean ± SEM, n = 7 young and n = 6–7 elderly IL-2/CD40-treated mice, n = 11 young and n = 12
elderly PBS control mice, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii) IL-2/CD40-treated mice to age-matched
PBS control mice.
elderly DCs (Figure 9A). In contrast, IL-2/CD40 induced
reduced MHC-I and CD80 (Supplementary Figure S7C)
in young, but not elderly, tumor-associated CD11c+
cells. Concurrently, IL-2/CD40 reduced expression of
several regulatory markers on young CD11c+ cells
including: CD39 (Supplementary Figure S7C), A2AR
(Supplementary Figure S7D), A2BR (Figure 9A) and PD-L1
(Supplementary Figure S7D), yet expression of CD73 increased
(Supplementary Figure S7D), relative to PBS controls. However,
elderly CD11c+ cells demonstrated reduced CD40 (Figure 9B)
and increased A2BR (Figure 9A) relative to young CD11c+
cells. Taken together, this suggests that IL-2/CD40 alleviates
suppressive CD11c+ cells in young, but not elderly tumors,
likely contributing to reduced tumor responses to IL-2/CD40 by
elderly mice.
IL-2/CD40 Reduces IFN-γ and Perforin on
Elderly Tumor-Infiltrating CD8+ T cells
Examination of tumor-associated T cells showed that
IL-2/CD40 reduced young, but not elderly, CD4+ T
cell (Supplementary Figure S8A) and Treg proportions
(Supplementary Figure S8A), leaving elevated Treg
proportions in elderly IL-2/CD40-treated tumors
(Supplementary Figure S8A), implying increased suppressive
activity in elderly tumors.
Regardless of age, IL-2/CD40 up-regulated CD25 on
tumor-associated CD8+ T cells (Figure 10A) relative to PBS
controls, this increase was more striking in young mice
(Figure 10A).
Several age-specific effects of IL-2/CD40 were also observed.
In elderly IL-2/CD40-treated tumors, IFN-γ+CD8+ T
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FIGURE 8 | IL-2/CD40 increases CTLA-4, ICOS, TGF-β, CD39, and LAG-3 on young and elderly TDLN CD4+ T cells. After two doses of IL-2/CD40 or PBS diluent,
percentages of CD4+ T cells positive for CTLA-4, ICOS and TGF-β (A) and CD39, LAG-3, CD73, and PD-1 (B) were measured in TDLNs from the young and elderly
tumor-bearing mice described in Figures 5B,C using flow cytometry. Data are shown as mean ± SEM, n = 7 young and n = 6–7 elderly IL-2/CD40-treated mice,
n = 11 young and n = 12 elderly PBS control mice, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001 comparing (i) young to elderly mice, or (ii)
IL-2/CD40-treated mice to age-matched PBS control mice.
cells (Figure 10A) and perforin levels on CD8+ T cells
(Figure 10B) reduced compared to controls. This was
accompanied by reductions in tumor-associated CD8+ T
cells expressing CD73 (Supplementary Figure S8B) and IL-10
(Supplementary Figure S8B) in elderly, but not young, IL-
2/CD40-treated mice, relative to PBS controls. Overall, despite
the observation that IL-2/CD40 alleviates certain suppressive
functions in elderly tumor-infiltrating CD8+ T cells, these cells
also demonstrated reduced anti-tumor effector function.
Unexpectedly, IL-2/CD40 promoted a more regulatory
phenotype in young tumor-associated CD8+ T cells, on
account of increases in several regulatory markers, relative
to PBS controls, specifically: CD39, A2AR, A2BR, ICOS,
LAG-3, and PD-1 (Supplementary Figures S8B,C). As
a result, expression of CD39, A2AR, A2BR, ICOS and
LAG-3 (Supplementary Figures S8B,C) was higher on
tumor-associated CD8+ T cells from young, compared to
elderly, IL-2/CD40-treated mice. These data may reflect
transition of young CD8+ T cells to the attenuation
phase of the immune response following IL-2/CD40
stimulation.
IL-2/CD40 Reduces CTLA-4, ICOS and
IL-10-Mediated Suppressive Potential in
Young, but not Elderly, Tumor-Infiltrating
CD4+ T Cells
IL-2/CD40 reduced CD25 (Figure 10C) and IFN-γ (Figure 10C)
in tumor-associated CD4+ T cells in both age groups alongside
reductions in the regulatory markers CD73 (Figure 10C)
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FIGURE 9 | Increased IFN-γ, TGF-β, and A2BR, and reduced CD40 on CD11c+ cells from elderly IL-2/CD40-treated tumors. After two doses of IL-2/CD40 or PBS
diluent, percentages of CD11c+ cells positive for IFN-γ, TGF-β and A2BR (A) and expression levels of CD40 (shown as geometric mean fluorescence intensity; MFI)
on CD11c+ cells (B) were measured from the young and elderly tumor-bearing mice described in Figures 5B,C using flow cytometry. Data are shown as mean ±
SEM, n = 7 young and n = 7 elderly IL-2/CD40-treated mice, n = 6–11 young and n = 7–12 elderly PBS control mice, *p < 0.05, **p < 0.005, ***p < 0.0005
comparing (i) young to elderly mice, or (ii) IL-2/CD40-treated mice to age-matched PBS control mice.
and CTLA-4 (Figure 10D). The reduction in CTLA-4 was
more striking for young mice (Figure 10D). Furthermore,
young, but not elderly, IL-2/CD40-treated mice demonstrated
additional reductions in other regulatory markers expressed
by tumor-associated CD4+ T cells, including ICOS and IL-
10 (Figure 10D). Reduction of several layers of suppression in
young tumor-associated CD4+ T cells may help account for the
improved tumor response seen in young mice to IL-2/CD40
treatment.
Reduced Tumor-Specific CTL Activity in
Elderly TDLNs and Tumors Is not Restored
by IL-2/CD40
The data above suggests elderly CD8+ T cells have reduced
effector function and increased suppressive function, therefore
we assessed the cytolytic capacity of young vs. elderly tumor-
specific CD8+ T cells in TDLNs and tumors after two doses of IL-
2/CD40 using an in vivo CTL assay. This assay uses AE17sOVA-
bearing young and elderly mice, where ovalbumin acts as a
marker tumor antigen, enabling measurement of antigen-specific
CTL responses against SIINFEKL, the dominant peptide of
ovalbumin. SIINFEKL-pulsed and unpulsed control target cells
were injected into young and elderly AE17sOVA-bearing mice
treated with PBS diluent or IL-2/CD40. 24 h later LNs and
tumors were removed and lysis of SIINFEKL-labeled target
cells measured to provide an indication of tumor-specific CTL
activity. Significantly reduced SIINFEKL-specific lytic activity
was observed in TDLNs (Figure 11A) and tumors (Figure 11B)
of elderly IL-2/CD40-treated and PBS control mice, relative to
their younger counterparts (36). IL-2/CD40 induced increased
trends for CTL activity in young TDLNs (p = 0.08; Figure 11A)
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FIGURE 10 | Reduced CD25, IFN-γ and perforin on CD8+ T cells and increased CTLA-4 on CD4+ T cells in elderly IL-2/CD40-treated tumors. After two doses of
IL-2/CD40 or PBS diluent, percentages of CD8+ T cells positive for CD25 and IFN-γ (A), expression levels of perforin (shown as geometric mean fluorescence
intensity; MFI) on CD8+ T cells (B), and percentages of CD4+ T cells positive for CD25, IFN-γ and CD73 (C) and CTLA-4, ICOS and IL-10 (D) were measured in
tumors from the young and elderly tumor-bearing mice described in Figures 5B,C using flow cytometry. Data are shown as mean ± SEM, n = 7–10 young and
n = 7–11 elderly IL-2/CD40-treated mice, n = 11–14 young and n = 12–16 elderly PBS control mice, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001
comparing (i) young to elderly mice, or (ii) IL-2/CD40-treated mice to age-matched PBS control mice.
and tumors (p = 0.1; Figure 11B) whilst no increase in CTL
activity was observed in elderly IL-2/CD40-treated mice, relative
to PBS controls (Figures 11A,B). The age-related reduction in
tumor-specific CTL function in untreated (PBS) elderly tumor-
bearing mice may account for the faster tumor growth rate seen
in elderly mice. Poorer CTL responses in elderly mice is likely
to contribute to their reduced tumor responses to IL-2/CD40-
treatment.
DISCUSSION
Our study shows that aging programs development of a
suppressive immune environment, which is reflected by DCs
and T cells, and this may compromise generation of anti-
tumor immune responses, influence mesothelioma progression
and responses to IL-2/CD40 immunotherapy. We observed
establishment of a suppressive environment within healthy
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FIGURE 11 | Reduced tumor-specific CTL activity in elderly TDLNs and tumors. In a further experiment the cytotoxic activity of tumor-specific CD8+ CTLs was
assessed after two doses of IL-2/CD40 or PBS diluent in TDLNs (A) and tumors (B) of young (n = 17) and elderly (n = 17) AE17sOVA-bearing mice using an in vivo
CTL assay. SIINFEKL-pulsed and unpulsed target cells were injected into tumor-bearing mice, and ratios between percentages of the two target cell populations in
TDLNs and tumors measured 18 h later via flow cytometry. Data are shown for individual mice as well as mean ± SEM, mouse numbers differed on account of varying
cell numbers available for analysis and ranged from n = 8 young and n = 6–8 elderly IL-2/CD40-treated mice, n = 6–9 young and n = 7–9 elderly PBS control mice,
*p < 0.05, ***p < 0.0005, ****p < 0.0001 comparing young to elderly mice.
elderly LNs, evidenced by increased regulatory pathways on DCs
and T cells. This regulatory LN environment was maintained in
TDLNs of elderly mesothelioma-bearing mice. As TDLNs are
the main site of DC/T cell interactions leading to generation
of anti-tumor effector T cell responses, increased suppressive
mechanisms in elderly TDLNs likely led to compromised
generation of anti-mesothelioma effector T cell responses,
thereby contributing to the faster tumor growth rate observed in
the elderly.
Elevated pDCs in elderly LNs/TDLNs represents one
suppressive pathway that is likely to negatively affect elderly
anti-tumor immune responses, as pDCs have been associated
with immune suppression in cancer (37). There are several
mechanisms by which pDCs induce immune suppression,
including: (i) inducing Th1 cell anergy and apoptosis via
indoleamine 2,3-dioxygenase (IDO) (38), (ii) inhibiting Th1
cell proliferation via granzyme B (39), and (iii) promoting
suppressive Treg expansion via IDO (40, 41) and/or expression
of ICOS ligand (ICOS-L), which binds ICOS expressed on
Tregs, leading to Treg activation and IL-10 secretion (42–
45). In turn, Tregs mediate suppression within LNs, by
inhibiting effector CD8+ and CD4+ T cells, and promoting
regulatory function in DCs (46). Thus, the age-related increase
in LN/TDLN pDCs likely compromises the development of
effective anti-mesothelioma immune responses in the elderly.
Age-related increases in several regulatory markers on
LN/TDLN CD11c+ cells and T cells represents a further
mechanism that contributes to a suppressive environment in
the elderly. As the outcome of a T cell response depends
on the summation of positive and negative signals it receives
(47), age-related increases in regulatory molecules will skew
the balance in favor of negative signals, leading to elderly T
cell suppression, rather than activation. LN/TDLN CD11c+
cells demonstrated simultaneous increases in antigen-presenting
(MHC-I), co-stimulatory (CD80, IL-12, and IFN-γ) and
regulatory (CD73 and PD-L1) molecules with aging. Therefore,
whilst antigen presentation to T cells may be maintained with
aging, it is likely to be accompanied by an increased breadth of
negative signals. The strength of a signal delivered by a molecule
is determined by interaction with its ligand, and although we
observed increased CD80 expression on elderly LN CD11c+
cells, others have reported that expression of its ligand, CD28,
is reduced on elderly T cells (48–51), suggesting reduced T cell
activation in the elderly. In this scenario, CD80 may instead play
a role in inhibiting T cell responses during aging. This study, and
others (52, 53), showed increased CTLA-4 expression on elderly
T cells; ligation of CD80 and CTLA-4 negatively regulates T cell
activation (54). Furthermore, CD80 on DCs can also bind PD-L1
on T cells, leading to T cell inhibition (55, 56), and others have
shown that PD-L1 expression is increased on aged CD8+ T cells
(57, 58). Thus, elevated CD80 on elderly CD11c+ cells may lead
to T cell suppression.
The PD-L1/PD-1 pathway represents another mechanism
by which T cell responses may be suppressed during aging.
In agreement with others, this study observed increased PD-
L1 expression on elderly LN CD11c+ cells (57), and increased
PD-1 expression on elderly LN/TDLN T cells (52, 53, 57, 59–
63), suggesting that the likelihood of inhibitory PD-L1/PD-1
interactions is increased with aging. The outcomes of this
include inhibition of T cell proliferation, reduced effector T
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cell differentiation, reduced cytokine production and cytotoxic
function, as well as increased T cell apoptosis (64–67), thereby
compromising elderly effector T cell responses.
In addition, the age-related increase in LAG-3 expression on
T cells, also observed in another study (62), may lead to increased
negative signaling through the MHC-II/T cell receptor complex
(68), and could contribute to the impaired ability of elderly DCs
to prime CD4+ T cells and Th1 responses, described by others
(7, 69, 70).
Increased CD73 on elderly CD11c+ cells represents another
mechanism of T cell suppression as it indicates increased
capacity to produce immunosuppressive adenosine, particularly
if neighboring cells express CD39 (71), such as the concomitant
increase in CD39 expression we observed on elderly TDLN
T cells. Elderly T cells also had increased CD73, suggesting
they contribute to the generation of adenosine. Moreover,
elderly CD4+ T cells in LNs/TDLNs have an increased capacity
to respond to adenosine due to elevated expression of the
adenosine-binding A2B receptor. Adenosine-mediated signaling
deactivates T cells by impairing IL-2 production (72, 73) and
inducing Tregs (74, 75). Taken together, our data suggests
that with aging, negative signals outweigh positive signals
during DC/T cell interactions in elderly LN/TDLNs, leading to
suppression of tumor-specific effector T cells. This is supported
by our observation that CTLs in elderly TDLNs displayed
reduced tumor antigen-specific cytolytic activity relative to their
younger counterparts. Taken together, these changes suggest
diminished anti-mesothelioma immune responses in the elderly,
contributing to faster tumor progression.
The age-induced up-regulation of several inhibitory markers
on LN/TDLN T cells not only suggests an increased capacity
to respond to negative signals from DCs, but also implies that
elderly T cells are functionally exhausted. In agreement with
others, we observed that elderly CD8+ and CD4+ T cells had
increased PD-1, CTLA-4, ICOS, LAG-3, and CD39 expression
(52, 53, 57, 59–63, 76, 77), with simultaneous up-regulation
of checkpoint inhibitory markers (particularly PD-1, CTLA-4,
LAG-3, TIM-3, and CD39) being a hallmark of exhausted T cells
(78, 79). This regulatory phenotype was accompanied by reduced
lytic effector function in elderly CD8+ T cells. T cell exhaustion
has been described in cancer (80–82) and is a state in which T
cells are unable to proliferate, produce lower levels of cytokines
such as IL-2 and IFN-γ, have diminished cytotoxic activity and
effector function, and cannot generate memory responses (78,
83). The development of an exhausted phenotype in aged T cells
is supported by studies showing that PD-1-expressing elderly T
cells are dysfunctional, as they have reduced proliferative capacity
(53, 57, 59, 63). Thus, aging-induced development of functionally
exhausted T cells with diminished anti-tumor effector activity
represents another potential mechanism contributing to faster
mesothelioma tumor growth in the elderly.
Examination of CD11c+ cells and T cells within tumors
provided further evidence that a suppressive immune
environment develops during aging. CD11c+ cells in elderly
tumors may have reduced ability to present antigens and
stimulate CD8+ and CD4+ T cells on account of decreased
MHC-I and II, and CD80. Generation of anti-tumor Th1
responses within elderly tumors may be further compromised
due to reduced CD4+ T cells and CD11b+CD8α−CD4+ cDCs
whose main role is activation of Th1 responses (84, 85). A
reduction in the ability of elderly CD11c+ cells to stimulate
anti-tumor effector T cells is consistent with other studies
showing that elderly bone marrow-derived DCs are less efficient
in stimulating tumor antigen-specific CD8+ and CD4+ T cells
and mediating tumor regression (6, 7), and that administration
of DC vaccines to elderly mice results in weak cytotoxic CD8+ T
cell activity and does not slow tumor growth (8, 9). In addition,
elderly tumor-associated CD11c+ cells may be further skewed
toward suppressive function due to increased IL-10 and TNF-α.
Production of IL-10 by DCs can lead to T cell inhibition and
induction of Tregs (86, 87), and TNF has recently been shown
to promote CD4+ T cell exhaustion in chronic viral infection
(88). Changes in elderly tumor-associated CD11c+ cells suggest
that the outcome of cross-talk between CD11c+ cells and T
cells in tumors is likely to be skewed toward generation of
suppressive T cells. This is supported by this study showing that
elderly tumor-associated CD8+ and CD4+ T cells had reduced
IFN-γ, implying reduced effector activity. Furthermore, elderly
tumor-associated CD8+ CTLs also demonstrated compromised
capacity to mediate tumor antigen-specific cell lysis and killing.
Our observations agree with other studies showing that T
cells in elderly tumor-bearing hosts are dysfunctional due to
impaired cytotoxic activity and reduced production of IFN-γ
and IL-2 (10–18). Additionally, our data suggest that elderly
tumor-infiltrating CD8+ T cells are skewed toward suppressive
function, due to increased CD73, suggesting increased potential
to generate adenosine. Our parallel studies have also shown
that elderly mesothelioma tumors contain increased tumor-
associated macrophages (Duong et al. under review) which
represent another layer of immune suppression. Thus, the
elderly tumor microenvironment represents another site of
increased immune suppression, which may disable local anti-
tumor immune responses contributing to faster mesothelioma
growth.
The increased regulatory status of elderly DCs and T cells
may not only affect tumor progression, but also the efficacy
of anti-tumor immunotherapies, which is supported by our
data showing that IL-2/CD40 immunotherapy is less effective in
inducing mesothelioma regression in elderly mice. IL-2/CD40
slowed tumor growth in both age groups (completely in
young, partially in elderly) and this may be explained by our
observations that IL-2/CD40 induced several common effects on
tumor-infiltrating CD11c+ cells, CD8+ T cells, and CD4+ T cells
from both age groups. Elevated IFN-γ expression by CD11c+
cells, and increased CD25 expression by CD8+ T cells suggests
these cells are more activated with increased effector function
and contribute to IL-2/CD40-induced slowing of tumor growth.
This is supported by studies from our laboratory showing that
CD8+ T cells are important anti-tumor effector cells during
IL-2/CD40 treatment (26, 29), and other studies showing that
DCs, CD8+ T cells and IFN-γ are required for IL-2/CD40-
mediated tumor regression (89–92). Additionally, reduced CD25,
CD73, and CTLA-4 on tumor-infiltrating CD4+ T cells in both
age groups suggest reduced Treg-mediated suppression within
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IL-2/CD40-treated tumors. This is supported by other studies
showing that IL-2/CD40 alleviates Treg suppression in murine
tumors (89, 93). Importantly, IL-2/CD40 also reduced expression
of several regulatory markers on young and elderly TDLN
CD11c+ cells (CD39, CD73, TGF-β, and IL-10), suggesting
alleviation of adenosine, TGF-β and IL-10-mediated suppression
in TDLNs, which may create a more permissive environment
for generation of IL-2/CD40-induced effector T cell responses.
Collectively, these changes may contribute to the IL-2/CD40-
induced slowing of tumor growth observed in both age groups.
Nonetheless, IL-2/CD40 was less effective in elderly tumor-
bearing mice, which could be attributed to an exacerbated
suppressive environment in elderly TDLNs. Although MHC-I
and II increased on TDLN CD11c+ cells in elderly IL-2/CD40-
treated mice, suggesting increased antigen presentation to T
cells, this is likely to be accompanied by negative co-stimulatory
signals, due to concomitant reductions in CD40 and CD80, and
the observation that IL-2/CD40 did not overcome age-related
increases in suppressive CD73 and TGF-β on elderly CD11c+
cells. Moreover, elderly TDLN CD8+ and CD4+ T cells may
be more suppressive/exhausted and more responsive to negative
signals from antigen-presenting cells, as age-related increases
in CTLA-4, ICOS, TGF-β, A2AR, CD39, LAG-3, and/or PD-
1 were further enhanced during IL-2/CD40 treatment. Further
evidence for reduced generation of effector T cells in TDLNs
of IL-2/CD40-treated elderly mice comes from the observation
that elderly TDLN CD8+ T cells failed to up-regulate perforin
and antigen-specific cytolytic effector function in response to IL-
2/CD40, unlike their younger counterparts; this shows that anti-
tumor cytotoxic effector T cell responses are compromised in
the elderly. As previous studies from our laboratory have shown
that CD8+ T cells and perforin-associated effector function are
important for IL-2/CD40-mediated tumor regression in young
mice (26), this likely contributes to poorer tumor responses by
elderly mice to IL-2/CD40.
IL-2/CD40 alleviated suppression in young, but not elderly
tumors, which also accounts for the better responses of young
mice to IL-2/CD40 immunotherapy. Specifically, IL-2/CD40
reduced expression of several regulatory molecules (CD39,
A2AR, A2BR, PD-L1, ICOS, and/or IL-10) on young tumor-
infiltrating CD11c+ cells and CD4+ T cells, suggesting reduced
suppressive activity. In contrast, CD11c+ cells and T cells
infiltrating elderly IL-2/CD40-treated tumors were characterized
by an increased regulatory and reduced effector status. Elderly
CD11c+ cells displayed reduced CD40 expression, suggesting a
reduced ability to license T cells (94, 95). This was associated
with: (i) increased A2BR, implying an increased capacity of
CD11c+ cells to respond to adenosine, leading to induction
of tolerogenic/inhibitory DCs (96–98), and (ii) increased TGF-
β, via which DCs suppress effector T cells and promote Tregs
(99, 100); the latter is supported by elevations in Treg proportions
and CTLA-4 expression on CD4+ T cells in elderly IL-2/CD40-
treated tumors. Moreover, elderly tumor-associated CD8+ T
cells demonstrated decreased perforin and IFN-γ implying
reduced effector function; this is supported by our observation
that elderly tumor-associated CTLs failed to up-regulate lytic
function in response to IL-2/CD40, and represents another
mechanism which reduces the efficacy of IL-2/CD40-mediated
tumor regression in the elderly (26, 89, 90, 92). As the age-related
differences in TDLN and tumor-infiltrating CD11c+ cells and
T cells reported in this study were observed after one-third of
the usual IL-2/CD40 schedule, further studies are required to
examine CD11c+ cells/DCs and T cells after a complete schedule
of IL-2/CD40.
Collectively, our data suggests that checkpoint blockade of
inhibitory molecules may improve responses to IL-2/CD40
immunotherapy in elderly hosts with mesothelioma. In
particular, blockade of multiple inhibitory molecules (CD39,
CD73, A2A, and A2B receptors, PD-L1, PD-1, CTLA-4, LAG-3,
ICOS, and TGF-β) will help reduce the likelihood of negative
cross-talk during DC/T cell interactions in elderly TDLNs and
tumors, thereby permitting activation of anti-tumor effector T
cells. A few recent studies have reported promising results for
elderly melanoma, non-small cell lung cancer and renal cancer
patients treated with CTLA-4 or PD-1 blockade, with elderly
patients demonstrating similar survival benefits and ability to
tolerate treatments, compared to younger patients (101–104),
this supports further investigation of checkpoint blockade as a
therapeutic avenue for elderly mesothelioma patients.
In conclusion, our study has shown that aging programs
a suppressive immune environment in healthy elderly LNs,
characterized by increased suppressive pDCs, and elevated
expression of several regulatory markers on CD11c+ cells
and T cells. This regulatory environment is maintained
in TDLNs of elderly mesothelioma-bearing mice, and is
accompanied by increased suppression in the elderly tumor
microenvironment. Thus, there is a greater summation
of negative signals during elderly DC/T cell interactions,
leading to effector T cell suppression and/or generation
of Tregs, resulting in reduced anti-mesothelioma immune
responses, that altogether contribute to faster tumor growth.
Furthermore, the age-related suppressive status of elderly
TDLN CD11c+ cells and T cells was exacerbated during IL-
2/CD40 immunotherapy, which may have contributed to its
reduced efficacy in elderly mice with mesothelioma. These
data suggest that combining IL-2/CD40 with checkpoint
blockade targeting multiple regulatory molecules could improve
the efficacy of anti-cancer therapies in elderly hosts with
mesothelioma.
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